Avodart (dutasteride), a new drug for benign prostatic hyperplasia

December 2002

GlaxoSmithKline is now marketing Avodart (dutasteride), a new drug for benign prostatic hyperplasia.

It's being promoted as better than Proscar (finasteride) because it blocks the two types of 5-alpha reductase.

Proscar selectively blocks only type 2.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

New generics for Prilosec (omeprazole) will soon hit the market
Diabetes Some diabetes patients are getting into trouble because they think all "clear" insulin is rapid-acting
Cardiology using digoxin in WOMEN with heart failure might do more harm than good
Cardiology new approaches for preventing a SECOND heart attack
Obesity & Weight Loss Topamax (topiramate) for obesity
Abilify (a-BILA-fī), a new antipsychotic for schizophrenia
Now that Claritin (loratadine) is OTC, many insurance plans will stop paying for some prescription antihistamines
Commit Lozenge is the newest OTC option to help smokers quit
allergic reactions to Bextra
Men's Health Avodart (dutasteride), a new drug for benign prostatic hyperplasia
Dermatology duct tape for common warts
Cholesterol statins do much more than just lower cholesterol
Natural Medicines questions about coral calcium
Gastroenterology irritable bowel syndrome (IBS) patients can benefit from SSRIs
questions about smallpox
Practice NON-stimulant ADHD drug, Strattera (atomoxetine)